FY2026 EPS Estimate for TuHURA Biosciences Lifted by Analyst

TuHURA Biosciences, Inc. (NASDAQ:HURA – Free Report) – Stock analysts at Brookline Capital Markets increased their FY2026 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a report issued on Monday, November 16th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings per share of ($0.46) for the year, up from their prior forecast of ($0.58). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.50) per share. Brookline Capital Markets also issued estimates for TuHURA Biosciences’ Q4 2026 earnings at ($0.10) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.48 EPS.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04.

HURA has been the subject of several other reports. Citizens Jmp restated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. HC Wainwright reiterated a “buy” rating on shares of TuHURA Biosciences in a research note on Tuesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

View Our Latest Stock Report on HURA

TuHURA Biosciences Trading Down 8.1%

NASDAQ HURA opened at $1.25 on Thursday. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43. The stock has a market cap of $82.20 million, a P/E ratio of -2.50 and a beta of -0.23. The stock’s fifty day moving average price is $1.85 and its 200-day moving average price is $2.02. The company has a current ratio of 0.47, a quick ratio of 0.18 and a debt-to-equity ratio of 0.49.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in HURA. BlackRock Inc. bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $1,615,000. Jefferies Financial Group Inc. purchased a new stake in TuHURA Biosciences during the 2nd quarter valued at $98,000. Invst LLC purchased a new stake in TuHURA Biosciences during the 2nd quarter valued at $99,000. Hsbc Holdings PLC purchased a new stake in TuHURA Biosciences during the 2nd quarter valued at $69,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of TuHURA Biosciences in the 2nd quarter worth $49,000. Institutional investors own 0.62% of the company’s stock.

More TuHURA Biosciences News

These are some of the HURA news items that stood out recently:

  • Positive Sentiment: HC Wainwright and Brookline Capital Markets raised multiple earnings-per-share forecasts, citing smaller projected losses in 2026–27. HC Wainwright lifted its FY2027 estimate to a loss of $0.39 per share from $0.61 and maintained a Buy rating; Brookline also raised estimates and now projects a return to profitability in 2029–30. Better forecasts may support investor sentiment, though they remain analyst projections. TuHURA Biosciences analyst coverage
  • Neutral Sentiment: The estimates still imply losses in the near term, and the articles report no new clinical, regulatory, or business development explaining the stock’s recent weakness. TuHURA earns Buy rating from HC Wainwright

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack. The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

Read More

Earnings History and Estimates for TuHURA Biosciences (NASDAQ:HURA)

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.